Designer drugs

Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA

Retrieved on: 
Tuesday, February 25, 2020
Pharmaceutical industry, Excipient, Health, Cannabinoids, Pharmaceutical sciences, Pharmacology, Designer drugs

OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for CAUMZ following the previously announced Type B meeting with the US Food and Drug Administration (FDA).

Key Points: 
  • OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for CAUMZ following the previously announced Type B meeting with the US Food and Drug Administration (FDA).
  • The highly purified cannabinoid molecules are also an important element in the future success of CAUMZ.
  • CAUMZ-kit results in the inhalation of cannabinoid molecules and not any compounds such as excipients, preservatives or oils.
  • As CAUMZ shares similarities to QIXLEEF, the FDA confirmed in the Type B meeting that CAUMZ would be eligible for waivers of some of the standard nonclinical toxicology studies.

Teewinot Announces Availability of Cannabinol for Commercial Cannabinoid Market

Retrieved on: 
Thursday, October 17, 2019
Cannabinoid, Designer drugs, Synthetic cannabinoids

With this announcement, Teewinot has become the first company capable of manufacturing cannabinol using chemical synthesis at commercial scale for individual purchase or under supply agreements.

Key Points: 
  • With this announcement, Teewinot has become the first company capable of manufacturing cannabinol using chemical synthesis at commercial scale for individual purchase or under supply agreements.
  • In addition, Teewinot has developed biocatalytic processes using the CannSynthesis technology platform to produce the acid and varin forms of rare cannabinoids.
  • Today, this platform allows for Teewinot to deliver the widest and most diverse range of cannabinoids for the growing market demand.
  • Teewinot is revolutionizing the synthetic cannabinoid space with its cost-effective, commercial scale approach to meet the global growing demand for cannabinoid-based products to address unmet health, wellness, and therapeutic needs.

The Werc Shop Awarded Patent on Novel Cannabinoid and Terpene Coating Technology

Retrieved on: 
Tuesday, October 8, 2019
WERC, Designer drugs, Cannabinoids

LOS ANGELES, Oct. 8, 2019 /PRNewswire/ -- The Werc Shop (TWS), a leader in cannabis manufacturing and formulation technology, was recently provided issuance notification of U.S. patent 10,434,084 entitled "Cannabinoid Blends and Formulations, Related Methods" by the United States Patent & Trademark Office (USPTO).

Key Points: 
  • LOS ANGELES, Oct. 8, 2019 /PRNewswire/ -- The Werc Shop (TWS), a leader in cannabis manufacturing and formulation technology, was recently provided issuance notification of U.S. patent 10,434,084 entitled "Cannabinoid Blends and Formulations, Related Methods" by the United States Patent & Trademark Office (USPTO).
  • This patent deals with the use of advanced mixing techniques to homogenously coat solid particles with cannabinoids, terpenes, or other substances.
  • "This is a green-chemistry advance in the formulation of standardized and stabilized cannabinoid and terpene flowable powders," says Jeffrey C. Raber, Ph.D., CEO of The Werc Shop.
  • This patent is the newest addition to the burgeoning, global portfolio of intellectual property created by The Werc Shop.

MCTC Files Third Cannabinoid Delivery Patent - 4D Printed Cannabinoid and Active Ingredient Delivery System

Retrieved on: 
Wednesday, October 2, 2019
Designer drugs, Cannabinoids, Organofluorides

The recent provisional patent filing is for a unique 4D, shape changing cannabinoid and active ingredient delivery system for beverages and some foods.

Key Points: 
  • The recent provisional patent filing is for a unique 4D, shape changing cannabinoid and active ingredient delivery system for beverages and some foods.
  • The technology can be used with various forms of cannabinoid infusion technologies, including MCTC patent pending cannabinoid nanoparticle technology, which utilizes a water soluble form of vitamin E as a bioenhancer.
  • This is an additional innovation for cannabinoid delivery produced by MCTC, commented Arman Tabatabaei, CEO of the Company.
  • We see many applications for this technology both within the cannabinoid industry and relative to the delivery of other active ingredients.

The global 1,4-butanediol (BDO), polytetramethylene ether glycol (PTMEG) and spandex market size is expected to reach USD 24.59 Billion by 2025

Retrieved on: 
Tuesday, August 27, 2019
Chemistry, Psychoactive drugs, Alkanediols, Organic compounds, Functional groups, Designer drugs, Sedatives, Elastomers, 1,4-Butanediol, Tetrahydrofuran, Butanediol, BDO

1,4-Butanediol (BDO), Polytetramethylene Ether Glycol (PTMEG) & Spandex Market Size, Share & Trends Analysis Report By Application (THF, PBT, Urethanes, Textiles), By Region, And Segment Forecasts, 2019 - 2025

Key Points: 
  • 1,4-Butanediol (BDO), Polytetramethylene Ether Glycol (PTMEG) & Spandex Market Size, Share & Trends Analysis Report By Application (THF, PBT, Urethanes, Textiles), By Region, And Segment Forecasts, 2019 - 2025
    Download the full report: https://www.reportbuyer.com/product/5807267/?utm_source=PRN The global 1,4-butanediol (BDO), polytetramethylene ether glycol (PTMEG) and spandex market size is expected to reach USD 24.59 Billion by 2025.
  • Rapid industrialization and exponential GDP growth in emerging markets such as India, Mexico, Brazil, Indonesia, and Thailand is expected to boost the growth.
  • Moreover, increasing sports activities and consumer awareness regarding fitness and healthy lifestyles is estimated to drive the market growth over the projected period.
  • These initiatives are expected to further boost the global BDO market over the forecast period.

Global Maleic Anhydride (1,4-BDO, UPR, Additives, Copolymers) Market Size, Share & Trends Analysis Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 1, 2019
Professional services, Consulting, Psychoactive drugs, Chemistry, Chemical compounds, Designer drugs, Sedatives, 1,4-Butanediol, Alkanediols, Prodrugs, Plastics, Polyurethane, Tetrahydrofuran, Maleic anhydride

The "Maleic Anhydride Market Size, Share & Trends Analysis Report By Application (1,4-BDO, UPR, Additives, Copolymers), By Region (Asia Pacific, North America, Europe, Central & South America, MEA), And Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Maleic Anhydride Market Size, Share & Trends Analysis Report By Application (1,4-BDO, UPR, Additives, Copolymers), By Region (Asia Pacific, North America, Europe, Central & South America, MEA), And Segment Forecasts, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • Maleic anhydride is used to manufacture 1,4-Butanediol (BDO), which has a high demand from the textile industry and the manufacturers of Tetrahydrofuran (THF) and Polyurethane (PU).
  • 1,4-BDO is an organic compound used as an industrial solvent & cleaner and glue remover.
  • Growing construction sector in Eastern Europe will further augment the demand for maleic anhydride.

Global and China 1, 4-butanediol (BDO) Markets 2019-2025: Supply and Demand, Competitive Landscape, Import and Export, Price Trends

Retrieved on: 
Monday, June 10, 2019
Psychoactive drugs, Designer drugs, Sedatives, 1,4-Butanediol, Alkanediols, Prodrugs, BDO

As of the end of 2018, the global BDO capacity reached approximately 4.3 million tons, of which about 53% came from Mainland China.

Key Points: 
  • As of the end of 2018, the global BDO capacity reached approximately 4.3 million tons, of which about 53% came from Mainland China.
  • Global and China 1,4-Butanediol (BDO) Industry Report, 2019-2025 highlights the followings:
    Global BDO industry (supply and demand, competitive landscape, price trend, etc.)
  • China BDO industry (supply and demand, competitive landscape, import & export, price trend, and development trend)
    BDO downstream industries like PTMEG, PBT, and GBL (supply and demand, competitive landscape, import and export, price trend, etc.)
  • 13 global and Chinese BDO manufacturers (operation and BDO business) and the progress of 16 Chinese Enterprises' BDO projects.

Geocann Announces Proven Stability Data Ensuring Desired Levels of Active Ingredients Are Maintained Throughout Promised Shelf-Life

Retrieved on: 
Thursday, May 9, 2019
Cannabinoids, Antiemetics, Resorcinols, Euphoriants, Designer drugs

FORT COLLINS, Colo., May 9, 2019 /PRNewswire/ --Geocann continues to set new industry standards in cannabinoid product safety and efficacy through its two-year stability data of hemp oil formulated with the patented VESIsorb delivery system.

Key Points: 
  • FORT COLLINS, Colo., May 9, 2019 /PRNewswire/ --Geocann continues to set new industry standards in cannabinoid product safety and efficacy through its two-year stability data of hemp oil formulated with the patented VESIsorb delivery system.
  • While many cannabinoid products are falling short of their label claims, Geocann's data confirms that the desired levels of key cannabinoids and terpenes are maintained from the first day of production to the last day of the promised shelf life.
  • "Our focus will always be on the safety of the consumer and the advancement and efficacy of cannabinoid products that deliver an extraordinary range of health benefits," said Jesse Lopez, CEO and founder.
  • The importance of stability data is often underestimated, especially in an emerging category like CBD where recent reports by the Food and Drug Administration (FDA), the Journal of the American Medical Association, and Consumer Lab, among many others, have shown that the majority of CBD products are falling short of their labeled claims.

Effective Solution to the Opioid Crisis in Cambridge

Retrieved on: 
Tuesday, May 7, 2019
Psychoactive drugs, Anilides, Piperidines, Chemical compounds, Synthetic opioids, Organic compounds, Designer drugs, Narconon, Fentanyl, Opioid

Overdose, especially from drugs laced with fentanyl, now kills more Canadians than car accidentsand without effective solutions, Canadian deaths can be expected to triple in the near future.

Key Points: 
  • Overdose, especially from drugs laced with fentanyl, now kills more Canadians than car accidentsand without effective solutions, Canadian deaths can be expected to triple in the near future.
  • Recent drug busts in Cambridge and elsewhere in the Waterloo Region show fentanyl is not only being used to boost opioid potency, but it is now being added to other street drugs such as methamphetamine, benzodiazepinesand even marijuana.
  • In response to the urgent demand for more rehabilitation programs and to help those looking for solutions for themselves or their loved ones, Narconon Cambridge has opened its doors to serve the community.
  • In this new facility in Cambridge, the Narconon program is delivered in a sober living environment.

2019 Pipeline Insight: Cannabinoid Receptor Type 1 (CB1) Antagonist - ResearchAndMarkets.com

Retrieved on: 
Friday, February 22, 2019
Health, Pharmaceutical, Branches of biology, Cell biology, Cannabinoids, G protein-coupled receptors, Designer drugs, Cannabinoid receptor type 1, CB1, Cannabinoid, Receptor, Penicillium parvum, Rosonabant

The "Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cannabinoid Receptor Type 1 (CB1) Antagonist development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Cannabinoid Receptor Type 1 (CB1) Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine